Author: GO2 for Lung Cancer Associate Director, Clinical Research, Andrew Ciupek, PhD With an increasing number of targeted therapies becoming available, making treatment decisions based on the results of biomarker testing has become an essential part of cancer care [...]
Every year, lung cancer professionals from across the globe gather to connect and learn at the World Conference for Lung Cancer (WCLC). Members of the GO2 team just returned from WCLC 2023 hosted in Singapore, where they presented GO2’s [...]
The American Society of Clinical Oncology (ASCO) hosts an annual meeting every spring where oncologists and other physicians, researchers, industry members, and advocacy organizations like GO2 come together to share and learn the latest and most exciting news on [...]
By Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer New research on metastatic (stage 4) non-small cell lung cancer (NSCLC) was a hot topic at the 2023 American Society of Clinical Oncology (ASCO) meeting. Data from [...]
By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer While the past decade has seen the development of many new therapies for lung cancer, these drugs are typically first approved for metastatic cancer (cancer that has [...]
Authors: Renee Botello, MSc, Treatment and Trial Navigator; Daniel A. Saez, MSc, Manager of LungMATCH Navigation Program In 2022, the treatment landscape for lung cancer continued to evolve to provide breakthrough treatment options for people living with lung cancer. This [...]
SAN CARLOS, Calif., (November 30, 2022) – The Addario Lung Cancer Medical Institute (ALCMI), a patient-founded not-for-profit global research consortium, has launched the SPARK Study to help researchers better understand treatment resistance in patients with KRAS-positive lung cancer and [...]
Authors: Renee Botello, MSc., Treatment and Trials Navigator; Andrew Ciupek, PhD, Associate Director, Clinical Research; Chief Scientific Officer Jennifer C. King, PhD; Shanada Monestime, PharmD, BCOP, Director, Community Engaged Research Every person’s cancer is different, which is why we [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program For many years, the treatment options given to patients diagnosed with early stage non-small cell lung cancer (NSCLC) was limited to surgery with or without chemotherapy to improve outcomes. However, [...]
What happens when your cancer becomes resistant to your course of treatment and progresses? That’s the question we explored in the September episode of our Lung Cancer Living Room series. Dr. David Gandara, professor emeritus and co-director of UC [...]